UroGen Pharma (LTS:0XOD) Change In Inventory: $-17.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0XOD UroGen Pharma Ltd LTS:0XOD
56 GF Score
Price $43.86
GF Value $27.96
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is UroGen Pharma Change In Inventory?

UroGen Pharma LTS:0XOD -0.83% 56 Change In Inventory is $-17.5 Mil as of Jun. 2026. GuruFocus rates LTS:0XOD with a GF Score™ of 56/100 and a GF Value™ of $27.96 (Significantly Overvalued). The stock has 9 warning signs investors should review.

UroGen Pharma's change in inventory for the quarter that ended in Jun. 2026 was $-3.7 Mil. It means UroGen Pharma's inventory increased by $3.7 Mil from Mar. 2026 to Jun. 2026 .

UroGen Pharma's change in inventory for the fiscal year that ended in Dec. 2025 was $-7.2 Mil. It means UroGen Pharma's inventory increased by $7.2 Mil from Dec. 2024 to Dec. 2025 .

UroGen Pharma's Total Inventories for the quarter that ended in Jun. 2026 was $24.6 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. UroGen Pharma's Days Inventory for the quarter that ended in Jun. 2026 was 315.95.

Inventory Turnover measures how fast the company turns over its inventory within a year. UroGen Pharma's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.29.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. UroGen Pharma's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.31.

UroGen Pharma  (LTS:0XOD) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

UroGen Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=22.755/6.572*365 / 4
=315.95

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

UroGen Pharma's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=6.572 / 22.755
=0.29

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

UroGen Pharma's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=22.755 / 72.456
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Change In Inventory Related Terms

UroGen Pharma Change In Inventory Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Change In Inventory Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.87 -0.36 -1.35 -3.55 -7.24

UroGen Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 -1.21 -8.12 -4.46 -3.67
LTS:0XOD
56GF Score
UroGen Pharma Ltd LTS:0XOD
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $-17.5 Mil mean?
UroGen Pharma (LTS:0XOD) has a Change In Inventory of $-17.5 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for UroGen Pharma and its competitors.
Is UroGen Pharma's Change In Inventory too high?
UroGen Pharma's current Change In Inventory is $-17.5 Mil. Overall, UroGen Pharma has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Change In Inventory compare to PVLA and KLRA?
UroGen Pharma's Change In Inventory of $-17.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for UroGen Pharma and its competitors. UroGen Pharma's current Change In Inventory is $-17.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $27.96, compared to a current price of $43.86 — trading 56.9% above its estimated fair value. The current Change In Inventory is $-17.5 Mil. UroGen Pharma's overall GF Score™ is 56/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Change In Inventory is $-17.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of $43.86 is trading 56.9% above its estimated GF Value™ of $27.96. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0XOD:

  • Change In Inventory: $-17.5 Mil
  • GF Value™: $27.96 vs. price of $43.86 (56.9% above fair value)
  • GF Score™: 56/100 with 9 warning signs

No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USAUR8:Germany
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
56GF Score

Get the complete analysis for LTS:0XOD

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.86
Price
$27.96
GF Value